Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
olatorepatide + alirocumab
- Development stage
- Unknown
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Peptides
- Administration
- Subcutaneous
01
Overview
olatorepatide + alirocumab is an investigational combination therapy being developed by Regeneron Pharmaceuticals for the treatment of obesity and associated cardiovascular risk factors, such as hypercholesterolemia. The combination consists of olatorepatide (HS-20094), a once-weekly dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist licensed from Hansoh Pharma, and Praluent (alirocumab), a marketed proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor monoclonal antibody. Olatorepatide promotes weight loss by regulating appetite, glucose metabolism, and energy balance, while alirocumab significantly lowers low-density lipoprotein cholesterol (LDL-C) levels. By combining these two mechanisms, the therapy aims to deliver robust body weight reduction alongside substantial lipid-lowering effects, addressing a critical therapeutic gap in cardiovascular risk management for patients with obesity.
- Other names
- alirocumab + HS-20094alirocumab + olatorepatideHS-20094 + alirocumabHS-20094 + Praluentolatorepatide + PraluentPraluent + HS-20094Praluent + olatorepatide
02
Targets
GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)PCSK9 (Proprotein convertase subtilisin/kexin type 9)
Beyond the preview
Go deeper on olatorepatide + alirocumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on olatorepatide + alirocumab.